SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it has submitted a cancer research grant application entitled “Affinity Capture of Circulating Cancer Biomarkers” to the National Institute of Health (NIH). As stated in the grant, the mortality rate of many cancers has remained relatively unchanged for decades. Even with advances in therapeutic care, there remains a critical unmet need to identify reliable cancer biomarkers that assist in early detection of cancer, monitor cancer treatment, and detect cancer recurrence. The grant submission details the adaptation of the Aethlon Hemopurifier® to function as an ultra-sensitive method to isolate and identify multiple cancer biomarkers in the blood. At present, the identification of cancer biomarkers is limited as only small blood samples can be extracted from the patient for testing. In the application submitted by Aethlon, the Hemopurifier® would assist in the identification of low-abundant, previously undetected cancer biomarkers, by capturing and identifying biomarkers from large blood volumes, including from the entire circulatory system. There is no assurance Aethlon will derive grant income related to this research initiative.
